One World Products, Inc.
OWPC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OWPC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OWPC
One World Products, Inc. (OWPC) is a pre-revenue development-stage company focused on the cannabis industry, with no current revenue and a going concern warning due to minimal cash and negative working capital.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$120K
Cash Runway
—
Lead Asset
cannabis (Approved)
Next Catalyst
—
Financial data as of Sep 30, 2025.
Tracking 1 pipeline candidate for One World Products, Inc..
One World Products, Inc. (OWPC) is a pre-revenue development-stage company focused on the cannabis industry, with no current revenue and a going concern warning due to minimal cash and negative working capital.
- As of September 30, 2025, the company reported total revenue of $0.0M and net income of $5.3M, with shareholders' equity of -$9.9M [sec].
- As of June 30, 2025, cash on hand was $13,615, negative working capital of $3,198,254, and an accumulated deficit of $31,386,280 [sec_mda · as of 2025-09-19].
- The company has repeatedly disclosed substantial doubt about its ability to continue as a going concern, stating it is 'too early in our development stage to project future revenue levels' [sec_mda · as of 2025-09-19].
- Financing activities have been the primary source of cash, with net cash provided by financing of $1,208,500 for the six months ended June 30, 2024 [sec_mda · as of 2024-08-21].
- The company has negative working capital and has relied on debt and equity financing to fund operations, with no indication of near-term revenue generation [sec_mda · as of 2025-09-19].
What works
- The company raised approximately $250,000 from a related party in April 2025, indicating some ongoing access to financing [sec_mda · as of 2025-06-03].
- Net cash provided by financing activities has been positive in recent periods, with $1,208,500 in the six months ended June 30, 2024 [sec_mda · as of 2024-08-21].
- The company reported net income of $5.3M as of September 30, 2025, though this appears to be from non-operational sources given zero revenue [sec].
What to weigh
- The company has zero revenue and is pre-revenue, with no projection of future revenue levels [sec_mda · as of 2025-09-19].
- Cash on hand was only $13,615 as of June 30, 2025, with negative working capital of $3.2M, raising substantial doubt about going concern [sec_mda · as of 2025-09-19].
- Accumulated deficit has grown to $31,386,280 as of June 30, 2025, reflecting persistent losses [sec_mda · as of 2025-09-19].
- The company has negative shareholders' equity of -$9.9M as of September 30, 2025 [sec].
From the filings
Quoted directly from source documents.
The company has minimal cash and negative working capital, raising going concern doubts.
“As of June 30, 2025, our balance of cash on hand was $13,615 and we had negative working capital of $3,198,254 and an accumulated deficit of $31,386,280.”
SEC MD&A · September 19, 2025
The company is pre-revenue and cannot project future revenue.
“We are too early in our development stage to project future revenue levels and may not be able to generate sufficient funds to sustain our operations for the next twelve months.”
SEC MD&A · September 19, 2025
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to minimal cash and negative working capital [sec_mda · as of 2025-09-19].
- No revenue generation — Company is pre-revenue with zero revenue and no near-term revenue projection [sec_mda · as of 2025-09-19].
- Negative equity — Shareholders' equity is negative $9.9M as of September 30, 2025, indicating liabilities exceed assets [sec].
- Dependence on financing — Operations rely entirely on debt and equity financing, with no assurance of future funding [sec_mda · as of 2025-09-19].
What to watch
- Ability to raise additional capital to fund operations and address going concern [sec_mda · as of 2025-09-19].
- Any progress toward revenue generation or commercialization of cannabis products [sec_mda · as of 2025-09-19].
- Changes in cash position and working capital in future filings [sec_mda · as of 2025-09-19].
- Regulatory developments in the cannabis industry that could affect the company's business model [sec_mda · as of 2025-09-19].
Sources: SEC MD&A · Generated August 2, 2026 · How we verify sources →
Run One World Products, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available One World Products, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$145K · Net income $5M
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for One World Products, Inc.?
One World Products, Inc. (OWPC) is a pre-revenue development-stage company focused on the cannabis industry, with no current revenue and a going concern warning due to minimal cash and negative working capital.
What is One World Products, Inc.'s lead drug candidate?
One World Products, Inc.'s most advanced tracked candidate is cannabis (Approved) for Medical conditions including pain, muscle spasticity, nausea.
Who is the CEO of One World Products, Inc.?
Mr. Isiah L. Thomas III is the chief executive officer of One World Products, Inc. (OWPC).
Where is One World Products, Inc. headquartered?
One World Products, Inc. (OWPC) is headquartered in Las Vegas, NV, United States.
What therapeutic areas does One World Products, Inc. focus on?
One World Products, Inc. develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.